AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home hLife Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Perspective | Open Access

Establishing a regulatory framework for phage therapy in China

Jixin Yang1,#, Haiyan Chen1,#, Xuesong He2, Nannan Wu3,4( ), Shuai Le1( ), Tongyu Zhu4 ( )
Department of Microbiology, College of Basic Medical Sciences, Key Laboratory of Microbial Engineering Under the Educational Committee in Chongqing, Army Medical University, Chongqing, China
Department of Microbiology, The American Dental Association Forsyth Institute, Massachusetts, USA
CreatiPhage Biotechnology Co., Ltd., Shanghai, China
Fudan University Phage Institute, Zhongshan Hospital Fudan University, Shanghai, China

#These authors contributed equally to this work

Show Author Information

References

【1】
【1】
 
 
hLife
Pages 554-557

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Yang J, Chen H, He X, et al. Establishing a regulatory framework for phage therapy in China. hLife, 2026, 4(9): 554-557. https://doi.org/10.1016/j.hlife.2026.05.001

3

Views

0

Crossref

Received: 13 April 2026
Revised: 27 April 2026
Accepted: 06 May 2026
Published: 01 September 2026
© 2026 The Author(s).

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).